Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 6Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Lymphoid 2CNS 2Plasma cell 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 386Skin Neoplasms 90Carcinoma, Non-Small-Cell Lung 78Breast Neoplasms 56Neoplasms 55Colorectal Neoplasms 52Lung Neoplasms 51Neoplasm Metastasis 46Ovarian Neoplasms 44Lymphoma, T-Cell, Cutaneous 44Carcinoma, Renal Cell 43Squamous Cell Carcinoma of Head and Neck 42Uveal Melanoma 39Pancreatic Neoplasms 37Sarcoma 35Carcinoma, Basal Cell 34Head and Neck Neoplasms 33Uterine Cervical Neoplasms 32Prostatic Neoplasms 32Stomach Neoplasms 30Carcinoma, Hepatocellular 30Endometrial Neoplasms 29Carcinoma, Merkel Cell 29Urinary Bladder Neoplasms 28Kidney Neoplasms 26Triple Negative Breast Neoplasms 24Esophageal Neoplasms 22Carcinoma, Squamous Cell 22Lymphoma 20Mycosis Fungoides 19

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Drug-Related Side Effects and Adverse Reactions × Dermatologic × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡